Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $95.00 short put and a strike $90.00 long put offers a potential 29.53% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $95.00 by expiration. The full premium credit of $1.14 would be kept by the premium seller. The risk of $3.86 would be incurred if the stock dropped below the $90.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 72.01 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
David Rolfe Comments on Celgene
Mon, 15 Apr 2019 21:54:34 +0000
We wrote in our last Letter that Celgene (NASDAQ:CELG) had recently announced it was being acquired by Bristol-Meyers Squibb in a $74 billion stock and cash acquisition. Over the course of the quarter, activist investors spoke out against the deal, large Bristol shareholders came out in support of it, and, finally, Institutional Shareholder Services (ISS) issued its opinion in favor of the deal going through. Warning! GuruFocus has detected 2 Warning Sign with CELG.
Celgene (CELG) Gains As Market Dips: What You Should Know
Mon, 15 Apr 2019 21:45:09 +0000
Celgene (CELG) closed at $95.10 in the latest trading session, marking a +1.02% move from the prior day.
David Rolfe's Wedgewood Partners 1st-Quarter 2019 Client Letter
Mon, 15 Apr 2019 21:02:15 +0000
Top first quarter performance detractors include Qualcomm, Berkshire Hathaway, Booking Holdings, Alphabet Class C, and Starbucks, plus Charles Schwab and C.H. Robinson. During the quarter we sold Qualcomm and trimmed positions in Ross Stores, Old Dominion Freight Line, and Charles Schwab.
Bristol-Myers' Shareholders Vote for Celgene Acquisition
Mon, 15 Apr 2019 17:53:05 +0000
Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
'One step closer to creating that great company' with Celgene, says Bristol-Myers CEO
Fri, 12 Apr 2019 22:50:04 +0000
Celgene brings to Bristol-Myers five late-stage products that could be approved in the near term, Caforio said.
Also on Market Tamer…
Follow Us on Facebook